Research Article| Volume 30, ISSUE 2, P192-198, February 1999

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT


      Background/Aims: There is consensus that interferon for hepatitis C should be stopped if alanine aminotransferase (ALT) remains elevated after 12 weeks; however, this may lead to unjust treatment withdrawal in around 20% of potential sustained responders. No consensus exists for interferon-ribavirin combination therapy. The aim of this study was to assess the predictive value of an HCV RNA test at 4 weeks in comparison with ALT, both in interferon monotherapy and in interferon-ribavirin combination therapy.
      Methods: Plasma HCV RNA was tested at 4 weeks in 149 naive patients undergoing 6 months and 187 undergoing up to 12 months of interferon monotherapy, and in 40 non-responders treated for 6 months with interferon-ribavirin combination therapy.
      Results: For 6 and up to 12 months of interferon monotherapy, the predictive value for non-response was 99% resp. 97% for a positive HCV RNA at week 4, versus 97% resp. 91% for an elevated ALT at week 12. Using a positive HCV RNA at week 4 as a stopping rule would lead to missing 5% resp. 12% of potential sustained responders, versus 10% resp. 28% for an elevated ALT at week 12. In interferon-ribavirin combination therapy, the predictive value for non-response was 100% for week 4 HCV RNA versus 95% for week 12 ALT, and 0% potential sustained responders were missed by a test for week 4 HCV RNA versus 20% for week 12 ALT. The overall sensitivity and specificity of a week 4 HCV RNA test was significantly better (area under ROC 0.85) as compared to testing ALT at week 4 (0.78, p<0.001), week 8 (0.76, p<0.001) or week 12 (0.78, p<0.001).
      Conclusion: A positive HCV RNA test (≥103 copies/ml) at 4 weeks is highly predictive for non-response and leads to significantly less misidentification of potential sustained responders than ALT at week 4, 8 or 12, both in 6 or up to 12 months interferon monotherapy and in 6 months interferon-ribavirin combination therapy of chronic hepatitis C.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Anonymous
        National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C..
        Hepatology. 1997; 26: 2S-10S
        • Dhumeaux D
        • Doffoel M
        • Galmiche JP
        A French consensus conference on hepatitis C: screening and treatment.
        J Hepatol. 1997; 27: 941-944
        • Chemello L
        • Bonetti P
        • Cavalletto L
        • Talato F
        • Donadon V
        • Casarin P
        • et al.
        Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group.
        Hepatology. 1995; 22: 700-706
        • Lin R
        • Roach E
        • Zimmerman M
        • Strasser S
        • Farrell GC
        Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
        J Hepatol. 1995; 23: 487-496
        • Poynard T
        • Bedossa P
        • Chevallier M
        • Mathurin P
        • Lemonnier C
        • Trepo C
        • et al.
        A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.
        N Engl J Med. 1995; 332: 1457-1462
        • Davis GL
        • Lau JY
        Factors predictive of a beneficial response to therapy of hepatitis C..
        Hepatology. 1997; 26: 122S-127S
        • Tong MJ
        • Blatt LM
        • McHutchison JG
        • Co RL
        • Conrad A
        Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison.
        Hepatology. 1997; 26: 1640-1645
        • Kleter GE
        • Brouwer JT
        • Heijtink RA
        • Schalm SW
        • Quint WG
        Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon.
        Antimicrob Agents Chemother. 1993; 37: 595-597
        • Brouwer JT
        • Nevens F
        • Kleter B
        • Elewaut A
        • Adler M
        • Brenard R
        • et al.
        Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
        J Hepatol. 1998; 28: 951-959
        • Brouwer JT
        • Nevens F
        • Michielsen P
        • Hautekeete ML
        • Chamuleau RAFM
        • Adler M
        • et al.
        What options are left when hepatitis C does not respond to interferon? Placebo controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon.
        J Hepatol. 1994; 21 ([abstract]): S17
        • Kleter GE
        • van Doorn LJ
        • Brouwer JT
        • Schalm SW
        • Heijtink RA
        • Quint WG
        Sequence analysis of the 5′ untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands.
        J Clin Microbiol. 1994; 32: 306-310
        • Lindsay KL
        Therapy of hepatitis C: overview.
        Hepatology. 1997; 26: 71S-77S
        • DeLong ER
        • DeLong DM
        • Clarke-Pearson DL
        Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
        Biometrics. 1988; 44: 837-845
        • Poynard T
        • Leroy V
        • Cohard M
        • Thevenot T
        • Mathurin P
        • Opolon P
        • et al.
        Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration.
        Hepatology. 1996; 24: 778-789
        • Schalm SW
        • Hansen BE
        • Chemello L
        • Bellobuono A
        • Brouwer JT
        • Weiland O
        • et al.
        Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centres.
        J Hepatol. 1997; 26: 961-966
        • Reichard O
        • Norkrans G
        • Fryden A
        • Braconier JH
        • Sonnerborg A
        • Weiland O Randomised
        double-blind, placebo-controlled trial of interferon alpha- 2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
        Lancet. 1998; 351: 83-87
        • Gavier B
        • Martincz-Gonzalez MA
        • Riezu-Boj JI
        • Lasarte JJ
        • Garcia N
        • Civeira MP
        • et al.
        Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C..
        Gastroenterology. 1997; 113: 1647-1653
        • Zeuzem S
        • Lee JH
        • Franke A
        • Ruster B
        • Prummer O
        • Herrmann G
        • et al.
        Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.
        Hepatology. 1998; 27: 1149-1156
        • Pawlotsky JM
        Measuring hepatitis C viremia in clinical samples: can we trust the assays?.
        Hepatology. 1997; 26: 1-4
        • Damen M
        • Cuypers HT
        • Zaaijer HL
        • Reesink HW
        • Schaasberg WP
        • Gerlich WH
        • et al.
        International collaborative study on the second EUROHEP HCV-RNA reference panel.
        J Virol Methods. 1996; 58: 175-185
        • Iino S
        • Hino K
        • Kuroki T
        • Suzuki H
        • Yamamoto S
        Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
        Dig Dis Sci. 1993; 38: 612-618
        • Bekkering FC
        • Brouwer JT
        • Leroux-Roels G
        • Vlierberghe H van
        • Elewaut A
        • Schalm SW
        Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy.
        J Hepatol. 1998; 28: 960-964